{"a":[{"_":"ITM neuroendocrine tumor drug spurned by FDA over manufacturing qualms","$":{"href":"/manufacturing/itm-neuroendocrine-tumor-drug-spurned-fda-over-manufacturing-qualms","hreflang":"en"}}]}
RegulatoryrejectedNegative
AI Analysis
Summary
The FDA has denied ITM Isotopes Technologies' lead pipeline candidate for neuroendocrine tumors due to manufacturing concerns.
Outcome Details
FDA denied approval due to manufacturing qualms
Importance:8/10
Sentiment:
-0.85
FDA rejectionmanufacturingneuroendocrine tumorrare disease
Read the original article
Published by FiercePharma on August 10, 2026 11:09 AM